Table 3 Influence of age and gender on comorbidities
From: The age again in the eye of the COVID-19 storm: evidence-based decision making
Age | Gender | ||||||
|---|---|---|---|---|---|---|---|
< 30 | 30–45 | 45–60 | 60–75 | > 75 | Male | Female | |
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Hypertensiona | |||||||
No | 7(5.6) | 19(15.2) | 41(32.8) | 41(32.8) | 17(13.6) | 67(53.6) | 58(46.4) |
Yes | 0(0) | 2(1.7) | 17(14) | 45(37.2) | 57(47.1) | 73(60.3) | 48(39.7) |
Dyslipidaemiaa | |||||||
No | 7(4.9) | 17(11.9) | 45(31.5) | 47(32.9) | 27(18.9) | 81(56.6) | 62(43.4) |
Yes | 0(0) | 4(3.9) | 15(14.7) | 38(37.3) | 45(44.1) | 59(57.8) | 43(42.2) |
Obesity | |||||||
No | 5(3) | 14(8.4) | 42(25.1) | 56(33.5) | 50(29.9) | 103(61.7) | 64(38.3) |
Yes | 1(2.9) | 2(5.9) | 7(20.6) | 18(52.9) | 6(17.6) | 17(50) | 17(50) |
Diabetesa | |||||||
No | 7(3.9) | 18(10.1) | 55(30.9) | 57(32) | 41(23) | 102(57.3) | 76(42.7) |
Yes | 0(0) | 3(4.4) | 5(7.4) | 31(45.6) | 29(42.6) | 40(58.8) | 28(41.2) |
Smokera,b | |||||||
No | 4(2.2) | 17(9.1) | 50(26.9) | 65(34.9) | 50(26.9) | 101(54.3) | 85(45.7) |
Yes | 3(12) | 1(4) | 7(28) | 6(24) | 8(32) | 20(80) | 5(20) |
Ex | 0(0) | 0(0) | 0(0) | 8(80) | 2(20) | 8(80) | 2(20) |
Primary immunodeficiencya | |||||||
No | 7(3) | 21(9) | 59(25.3) | 83(35.6) | 63(27) | 133(57.1) | 100(42.9) |
Yes | 1(50) | 0(0) | 0(0) | 0(0) | 1(50) | 1(50) | 1(50) |
Secundary immunodeficiency | |||||||
No | 5(2.7) | 16(8.6) | 52(28.1) | 60(32.4) | 52(28.1) | 98(53) | 87(47) |
Yes | 2(4.9) | 3(7.3) | 6(14.6) | 21(51.2) | 9(22) | 28(68.3) | 13(31.7) |
Epidemiological background | |||||||
NHR | 1(2.8) | 3(8.3) | 6(16.7) | 8(22.2) | 18(50) | 18(50) | 18(50) |
LIR | 1(1.9) | 5(9.6) | 15(28.8) | 16(30.8) | 15(28.8) | 31(59.6) | 21(40.4) |
FW | 1(7.1) | 1(7.1) | 7(50) | 4(28.6) | 1(7.1) | 5(35.7) | 9(64.3) |
CT | 3(6.7) | 7(15.6) | 12(26.7) | 23(51.1) | 13(51.1) | 38(65.5) | 20(34.5) |